The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved outcomes post-surgery and radiation.

A 63-year-old woman with a 20-year history of hidradenitis suppurativa, classified as Hurley Stage III (a disease-specific staging system); a 12 pack-year smoking history; pyoderma gangrenosum; and ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

Q. I am in my 60s and live in Australia. For the past 20 years, I’ve had numerous basal and squamous cell skin cancers removed. Every six months, I’d have to get another check and get something ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

MSK radiation oncologist Dr. Nancy Lee helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers. A phase 3 clinical trial ...

Expanding the industry’s most comprehensive portfolio of AI applicationsPHILADELPHIA and PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Proscia®, a pathology AI company, will add AI biomarker detection for ...